Melanoma is the most aggressive and deadly type of skin cancers, accounting for over 80% of skin cancer deaths despite representing only 1% of skin cancers.[1] Patients with advanced or metastatic melanoma have limited treatment options after tumor progression on immune‐checkpoint therapy and targeted therapy including v‐RAF murine sarcoma viral oncogene homolog B1 (BRAF)/mitogen‐activated protein kinase (MEK) inhibitors. The gene discussed is MAP2K7; the disease is skin neoplasm.